[Fibrinolysis of intraventricular hematoma with rt-PA].
Intraventricular administration of recombinant tissue plasminogen activator (rt-PA) is an experimental therapy to hasten the lysis of intraventricular hemorrhages. We report nine patients (7 male, 2 female, mean age 64a) with intracerebral hematoma with ventricular extension who were treated with intraventricular infusion of rt-PA (2-32 mg, mean dose 17 mg). In two patients, clinically significant bleeding complications were associated with the fibrinolytic therapy. In one of these patients, fibrinolytic therapy was stopped. Other complications could not be observed. In eight of all nine patients, a rapid and extensive reduction of the amount of intraventricular blood occurred. A persistent shunt became necessary in two patients. We conclude, that intraventricular fibrinolysis probably leads to a faster clearance of intraventricular blood. Despite of fibrinolytic treatment, a permanent shunt becomes necessary in some cases. Intraventricular fibrinolysis is a potentially hazardous therapy with the risks of bleeding complications and infection.
Schwarz
S
S
Neurologische Klinik, Universität, Heidelberg.
Schwab
S
S
Steiner
H H
HH
Hanley
D
D
Hacke
W
W
D000328:Adult; D000368:Aged; D002543:Cerebral Hemorrhage / Q000139:chemically induced / Q000000981:diagnostic imaging / Q000188:drug therapy*; D002552:Cerebral Ventricles / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D005260:Female; D006406:Hematoma / Q000139:chemically induced / Q000000981:diagnostic imaging / Q000188:drug therapy*; D006801:Humans; D007276:Injections, Intraventricular; D008297:Male; D008875:Middle Aged; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage* / Q000009:adverse effects; D014057:Tomography, X-Ray Computed
D010959:Tissue Plasminogen Activator